COMMUNIQUÉS West-GlobeNewswire
-
2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released
22/05/2026 -
SBC Medical and BLEZ ASIA Celebrate Opening of New Aesthetic Dermatology Section at BLEZ CLINIC in Bangkok
22/05/2026 -
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
22/05/2026 -
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
22/05/2026 -
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
22/05/2026 -
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
22/05/2026 -
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
22/05/2026 -
Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss
22/05/2026 -
Cartigenix HP® Backed by Three Human Studies as Clinicians Seek Evidence-Based Joint Health Options
22/05/2026 -
Enable Injections Announces CE Certification of the enFuse® On-Body Delivery System for Use with Aspaveli® Distributed by Sobi
22/05/2026 -
BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor
22/05/2026 -
American Shared Hospital Services Announces Annual Shareholder Meeting to be Held on June 24, 2026
22/05/2026 -
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
22/05/2026 -
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
22/05/2026 -
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial
22/05/2026 -
Repligen Corporation to Present at William Blair 46th Annual Growth Stock Conference
22/05/2026 -
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
22/05/2026 -
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
22/05/2026 -
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
22/05/2026
Pages